Aditxt, Inc. Sales Commissions and Fees
Aditxt, Inc. (ADTX) had Sales Commissions and Fees of $1.15 million as of 2022-08-04, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesCommissionsAndFees · last filed 2022-11-14
- 2022-08-04: Sales Commissions and Fees $1.15M.
| Period end | Sales Commissions and Fees |
|---|---|
| 2022-08-04 | $1.15M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |